Investors
Information for investors including share information, share analysis, shareholder news and annual reports.
Annual Report 2012
Download the full report (PDF)
View the report by section
Late-stage pipeline review
View the presentation slides (PDF)
View the webcast
Reasons to invest in GlaxoSmithKline - a leading pharmaceutical company enabling people to do more, feel better and live longer.
Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.
Press releases
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis
GlaxoSmithKline plc (GSK) today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis – a condition that involves inflammation of the blood vessels.
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
GlaxoSmithKline plc has announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine
GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) in response to the Biologics License Application (BLA) for its Pandemic Influenza A Virus Monovalent Adjuvanted candidate vaccine, referred to as Q-Pan H5N1.
|
GlaxoSmithKline plc |
Tel: +1 215 751 4000 |
|
5 Crescent Drive |
Fax: +1 919 315 3344 |
| Philadelphia, PA 19112 |
|
|
US |
